CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair

Autor: Shenoy, T.R., Boysen, G., Wang, M.Y., Xu, Q.Z., Guo, W., Koh, F.M., Wang, C., Zhang, L.Z., Wang, Y., Gil, V., Aziz, S., Christova, R., Rodrigues, D.N., Crespo, M., Rescigno, P., Tunariu, N., Riisnaes, R., Zafeiriou, Z., Flohr, P., Yuan, W., Knight, E., Swain, A., Ramalho-Santos, M., Xu, D.Y., de Bono, J. *, Wu, H. *
Zdroj: In Annals of Oncology July 2017 28(7):1495-1507
Databáze: ScienceDirect